After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...

Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...

On Wednesday, Novartis gave a more detailed look at long-awaited clinical data that the company believes will help secure a broad approval for a successor drug to its blockbuster gene therapy ...

No­var­tis re­leased two Phase 3 datasets on Wednes­day that show a new ver­sion of its gene ther­a­py Zol­gens­ma led to mo­tor func­tion im­prove­ments in pa­tients … ...